ABIONYX Pharma Future Growth

Future criteria checks 0/6

ABIONYX Pharma's revenue is forecast to decline at 17.7% per annum while its annual earnings are expected to grow at 1.1% per year. EPS is expected to decline by 0.6% per annum.

Key information

1.1%

Earnings growth rate

-0.6%

EPS growth rate

Biotechs earnings growth	37.0%
Revenue growth rate	-17.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 Mar 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:ABNXP - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	N/A	-9	N/A	-9	1
12/31/2024	4	-10	-13	-13	2
12/31/2023	2	-10	-14	-14	2
12/31/2022	3	-6	-6	-6	2
6/30/2022	3	-6	-6	-6	N/A
3/31/2022	2	-6	-7	-6	N/A
12/31/2021	1	-6	-7	-7	N/A
9/30/2021	0	-5	-6	-6	N/A
6/30/2021	0	-4	-6	-5	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	0	0	N/A
3/31/2020	N/A	0	-2	-2	N/A
12/31/2019	N/A	2	-4	-4	N/A
9/30/2019	0	1	-5	-5	N/A
6/30/2019	0	0	-6	-6	N/A
3/31/2019	0	-3	-6	-6	N/A
12/31/2018	0	-6	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	N/A	-8	-7	-7	N/A
3/31/2018	N/A	-6	-8	-8	N/A
12/31/2017	N/A	-5	-9	-9	N/A
9/30/2017	N/A	-8	-11	-11	N/A
6/30/2017	N/A	-11	-13	-13	N/A
3/31/2017	N/A	-18	-16	-16	N/A
12/31/2016	N/A	-25	-19	-19	N/A
9/30/2016	N/A	-25	-19	-19	N/A
6/30/2016	N/A	-24	-19	-19	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABNXP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABNXP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABNXP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABNXP's revenue is expected to decline over the next 3 years (-17.7% per year).

High Growth Revenue: ABNXP's revenue is forecast to decline over the next 3 years (-17.7% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABNXP's Return on Equity is forecast to be high in 3 years time

ABIONYX Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies